Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2005 1
2006 2
2007 1
2009 5
2010 2
2011 3
2012 8
2013 11
2014 11
2015 12
2016 13
2017 12
2018 9
2019 9
2020 7
2021 13
2022 9
2023 7
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

122 results

Results by year

Filters applied: . Clear all
Page 1
Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma - analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM.
Placke JM, Kimmig M, Griewank K, Herbst R, Terheyden P, Utikal J, Pföhler C, Ulrich J, Kreuter A, Mohr P, Gutzmer R, Meier F, Dippel E, Welzel J, Engel DR, Kreft S, Sucker A, Lodde G, Krefting F, Stoffels I, Klode J, Roesch A, Zimmer L, Livingstone E, Hadaschik E, Becker JC, Weichenthal M, Tasdogan A, Schadendorf D, Ugurel S. Placke JM, et al. Among authors: sucker a. EBioMedicine. 2023 Oct;96:104774. doi: 10.1016/j.ebiom.2023.104774. Epub 2023 Sep 4. EBioMedicine. 2023. PMID: 37660535 Free PMC article.
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.
Váraljai R, Zimmer L, Al-Matary Y, Kaptein P, Albrecht LJ, Shannan B, Brase JC, Gusenleitner D, Amaral T, Wyss N, Utikal J, Flatz L, Rambow F, Reinhardt HC, Dick J, Engel DR, Horn S, Ugurel S, Sondermann W, Livingstone E, Sucker A, Paschen A, Zhao F, Placke JM, Klose JM, Fendler WP, Thommen DS, Helfrich I, Schadendorf D, Roesch A. Váraljai R, et al. Among authors: sucker a. Nat Cancer. 2023 Sep;4(9):1395. doi: 10.1038/s43018-023-00632-w. Nat Cancer. 2023. PMID: 37580519 Free PMC article. No abstract available.
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.
Váraljai R, Zimmer L, Al-Matary Y, Kaptein P, Albrecht LJ, Shannan B, Brase JC, Gusenleitner D, Amaral T, Wyss N, Utikal J, Flatz L, Rambow F, Reinhardt HC, Dick J, Engel DR, Horn S, Ugurel S, Sondermann W, Livingstone E, Sucker A, Paschen A, Zhao F, Placke JM, Klose JM, Fendler WP, Thommen DS, Helfrich I, Schadendorf D, Roesch A. Váraljai R, et al. Among authors: sucker a. Nat Cancer. 2023 Sep;4(9):1292-1308. doi: 10.1038/s43018-023-00610-2. Epub 2023 Jul 31. Nat Cancer. 2023. PMID: 37525015 Free PMC article.
HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance.
Stupia S, Heeke C, Brüggemann A, Zaremba A, Thier B, Kretz J, Sucker A, Philip M, Zelinskyy G, Ferrone S, Roesch A, Horn S, Hadaschik E, Schadendorf D, Trilling M, Dittmer U, Griewank K, Zhao F, Paschen A. Stupia S, et al. Among authors: sucker a. Clin Cancer Res. 2023 Aug 1;29(15):2894-2907. doi: 10.1158/1078-0432.CCR-23-0099. Clin Cancer Res. 2023. PMID: 37199727
Glucocorticoid activation by HSD11B1 limits T cell-driven interferon signaling and response to PD-1 blockade in melanoma.
Martins Nascentes Melo L, Herrera-Rios D, Hinze D, Löffek S, Oezel I, Turiello R, Klein J, Leonardelli S, Westedt IV, Al-Matary Y, Egea-Rodriguez S, Brenzel A, Bau M, Sucker A, Hadaschik E, Wirsdörfer F, Hanenberg H, Uhlenbrock N, Rauh D, Poźniak J, Rambow F, Marine JC, Effern M, Glodde N, Schadendorf D, Jablonska J, Hölzel M, Helfrich I. Martins Nascentes Melo L, et al. Among authors: sucker a. J Immunother Cancer. 2023 Apr 7;11(4):e004150. doi: 10.1136/jitc-2021-004150. J Immunother Cancer. 2023. PMID: 37028818 Free PMC article.
Characterisation and outcome of RAC1 mutated melanoma.
Lodde GC, Jansen P, Herbst R, Terheyden P, Utikal J, Pföhler C, Ulrich J, Kreuter A, Mohr P, Gutzmer R, Meier F, Dippel E, Weichenthal M, Sucker A, Placke JM, Zaremba A, Albrecht LJ, Kowall B, Galetzka W, Becker JC, Tasdogan A, Zimmer L, Livingstone E, Hadaschik E, Schadendorf D, Ugurel S, Griewank K. Lodde GC, et al. Among authors: sucker a. Eur J Cancer. 2023 Apr;183:1-10. doi: 10.1016/j.ejca.2023.01.009. Epub 2023 Jan 18. Eur J Cancer. 2023. PMID: 36773463
Circulating cell-free messenger RNA enables non-invasive pan-tumour monitoring of melanoma therapy independent of the mutational genotype.
Albrecht LJ, Höwner A, Griewank K, Lueong SS, von Neuhoff N, Horn PA, Sucker A, Paschen A, Livingstone E, Ugurel S, Zimmer L, Horn S, Siveke JT, Schadendorf D, Váraljai R, Roesch A. Albrecht LJ, et al. Among authors: sucker a. Clin Transl Med. 2022 Nov;12(11):e1090. doi: 10.1002/ctm2.1090. Clin Transl Med. 2022. PMID: 36320118 Free PMC article.
Genetic and Methylation Analysis of CTNNB1 in Benign and Malignant Melanocytic Lesions.
Zaremba A, Jansen P, Murali R, Mayakonda A, Riedel A, Krahl D, Burkhardt H, John S, Géraud C, Philip M, Kretz J, Möller I, Stadtler N, Sucker A, Paschen A, Ugurel S, Zimmer L, Livingstone E, Horn S, Plass C, Schadendorf D, Hadaschik E, Lutsik P, Griewank K. Zaremba A, et al. Among authors: sucker a. Cancers (Basel). 2022 Aug 23;14(17):4066. doi: 10.3390/cancers14174066. Cancers (Basel). 2022. PMID: 36077603 Free PMC article.
122 results